Transport
Mercy Hospital Springfield
Mercy Hospital Springfield was paid $64.60M by Medicaid between Jan 2018 and Dec 2024, across 173 billing codes. Its largest line is Y7506, — 33% of everything it billed.
33Billing provider infoMERCY HOSPITAL SPRINGFIELD
SPRINGFIELD, MO 65804
SPRINGFIELD, MO 65804
33aNPI1578504056assigned 06/08/2006
33bProvider typeAir Ambulance
28Total paid$64.60M
24GClaims416,929
24DCodes billed173
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Air Ambulance providers in Missouri
Rank by total paid#1 of 14
Median peer was paid$593K
This provider vs. median109×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official ROBERTS, WILLIAM controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 65,941 | $20.30M | |
| 2019 | 68,970 | $17.85M | |
| 2020 | 52,536 | $6.89M | |
| 2021 | 50,638 | $2.38M | |
| 2022 | 51,398 | $4.20M | |
| 2023 | 64,522 | $6.95M | |
| 2024incomplete | 62,924 | $6.03M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| Y7506 | 33% | 82,874 | 68,082 | $21.16M | |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.9% | 20,732 | 19,906 | $6.41M |
| X4011 | State-specific procedure code | 7.9% | 21,117 | 19,858 | $5.12M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 6.7% | 75,357 | 67,987 | $4.30M |
| X4006 | 5.1% | 7,166 | 5,778 | $3.32M | |
| 80053 | Comprehensive metabolic panel | 5.1% | 62,072 | 57,957 | $3.31M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 4.3% | 15,161 | 14,753 | $2.79M |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | 4.2% | 950 | 941 | $2.71M |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | 3.7% | 1,857 | 1,814 | $2.40M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 2.8% | 7,392 | 7,174 | $1.81M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 2.4% | 20,290 | 18,238 | $1.52M |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 1.4% | 3,492 | 3,387 | $874K |
161 more codes
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.3% | 1,188 | $864K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.2% | 14,036 | $777K |
| X4003 | <1% | 4,063 | $589K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 3,388 | $400K |
| 88312 | <1% | 230 | $388K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 3,092 | $354K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 980 | $327K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 1,943 | $323K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,800 | $313K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 3,084 | $261K |
| 81003 | <1% | 4,798 | $234K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,705 | $227K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,461 | $223K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 3,297 | $198K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 387 | $191K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,785 | $188K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 394 | $183K |
| 43235 | <1% | 403 | $170K | |
| 88300 | <1% | 289 | $164K | |
| 71045 | Radiologic examination, chest; single view | <1% | 2,884 | $162K |
| G0378 | Hospital observation service, per hour | <1% | 145 | $157K |
| 81001 | <1% | 2,623 | $137K | |
| J3490 | Unclassified drugs | <1% | 6,740 | $124K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 353 | $98K |
| 82657 | <1% | 135 | $98K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 627 | $88K |
| 62323 | <1% | 416 | $81K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,829 | $81K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 825 | $80K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 5,043 | $64K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,759 | $64K |
| 47562 | <1% | 12 | $58K | |
| 93798 | <1% | 932 | $57K | |
| 95811 | <1% | 134 | $53K | |
| 64635 | <1% | 68 | $53K | |
| 83690 | <1% | 570 | $49K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 221 | $45K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,082 | $45K |
| 80081 | <1% | 389 | $37K | |
| D7999 | <1% | 12 | $35K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 360 | $34K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 516 | $34K |
| 88342 | <1% | 259 | $34K | |
| 42830 | <1% | 13 | $33K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 462 | $33K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 491 | $31K |
| G0260 | Injection procedure for sacroiliac joint; provision of anesthetic, steroid and/or other therapeutic agent, with or without arthrography | <1% | 119 | $30K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 972 | $30K |
| 82077 | <1% | 2,041 | $30K | |
| 84484 | <1% | 2,075 | $29K | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 816 | $25K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 522 | $23K |
| 81025 | <1% | 256 | $23K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 598 | $22K |
| 64493 | <1% | 52 | $22K | |
| 82397 | <1% | 811 | $22K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 26 | $18K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 45 | $18K |
| 87581 | <1% | 26 | $17K | |
| 87486 | <1% | 26 | $17K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 26 | $17K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 238 | $17K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 153 | $15K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 81 | $14K |
| 83605 | <1% | 331 | $13K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 189 | $12K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 13 | $11K |
| 64721 | <1% | 13 | $11K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 37 | $10K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 42 | $10K |
| 95819 | <1% | 41 | $9K | |
| 95816 | <1% | 62 | $9K | |
| 0099U | <1% | 19 | $7K | |
| 87081 | <1% | 40 | $7K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 93 | $7K |
| 83735 | <1% | 680 | $7K | |
| 36591 | <1% | 178 | $7K | |
| 43760 | <1% | 39 | $6K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 131 | $6K |
| 84305 | <1% | 133 | $5K | |
| 74018 | <1% | 139 | $5K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 147 | $5K |
| 59025 | Fetal non-stress test | <1% | 30 | $5K |
| 93296 | <1% | 309 | $4K | |
| 85046 | <1% | 271 | $4K | |
| 84100 | <1% | 153 | $4K | |
| 87075 | <1% | 618 | $4K | |
| 87070 | <1% | 618 | $4K | |
| Y7507 | <1% | 54 | $4K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 15 | $4K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 44 | $4K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 12 | $3K |
| 87176 | <1% | 545 | $3K | |
| Q3014 | Telehealth originating site facility fee | <1% | 97 | $3K |
| 93797 | <1% | 52 | $3K | |
| 87205 | <1% | 618 | $3K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 36 | $3K |
| 80143 | <1% | 158 | $3K | |
| 76770 | <1% | 38 | $3K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 29 | $3K |
| 86803 | <1% | 37 | $2K | |
| 94726 | <1% | 26 | $2K | |
| 27096 | <1% | 15 | $2K | |
| 82728 | <1% | 198 | $2K | |
| 80179 | <1% | 125 | $2K | |
| 85610 | <1% | 355 | $2K | |
| 43762 | <1% | 25 | $2K | |
| 97597 | <1% | 19 | $2K | |
| 93226 | <1% | 27 | $2K | |
| 84112 | <1% | 14 | $2K | |
| 87186 | <1% | 164 | $1K | |
| 95800 | <1% | 17 | $1K | |
| 88304 | <1% | 40 | $1K | |
| 77334 | <1% | 15 | $1K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 29 | $1K |
| 20553 | <1% | 12 | $1K | |
| 83880 | <1% | 25 | $1K | |
| 87077 | <1% | 107 | $1K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 111 | $950.01 |
| 82784 | <1% | 101 | $888.15 | |
| 84140 | <1% | 15 | $872.85 | |
| 83550 | <1% | 96 | $776.86 | |
| 96156 | <1% | 13 | $643.19 | |
| 83540 | <1% | 97 | $584.18 | |
| 51798 | <1% | 25 | $516.68 | |
| J2704 | Injection, propofol, 10 mg | <1% | 280 | $332.87 |
| 82947 | <1% | 136 | $325.93 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 145 | $278.00 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 289 | $266.68 |
| 85730 | <1% | 97 | $226.84 | |
| 94729 | <1% | 14 | $213.60 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 13 | $171.53 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 189 | $169.54 |
| 84702 | <1% | 12 | $163.70 | |
| 0641T | <1% | 163 | $156.48 | |
| 0240U | <1% | 17 | $142.63 | |
| 97161 | <1% | 15 | $96.69 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 487 | $82.44 |
| 85014 | <1% | 64 | $75.64 | |
| 85018 | <1% | 63 | $73.51 | |
| 84703 | <1% | 13 | $61.62 | |
| 86140 | <1% | 38 | $58.82 | |
| 82962 | <1% | 30 | $32.53 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 45 | $27.09 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 866 | $22.55 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 16 | $21.15 |
| 83655 | <1% | 68 | $19.36 | |
| 83615 | <1% | 19 | $5.44 | |
| 97116 | <1% | 36 | $3.24 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 13 | $2.41 |
| 11045 | 0% | 70 | $0.00 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 90 | $0.00 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 143 | $0.00 |
| 86850 | 0% | 12 | $0.00 | |
| 86592 | 0% | 13 | $0.00 | |
| C1769 | Guide wire | 0% | 15 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 41 | $0.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 68 | $0.00 |
| C1776 | Joint device (implantable) | 0% | 14 | $0.00 |
| 64636 | 0% | 15 | $0.00 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 0% | 22 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialROBERTS, WILLIAM (VICE PRESIDENT FINANCE)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.